Subscribe to stay informed!
Malvern-based Galera Therapeutics’ stock fell by more than 70 percent after the biopharmaceutical firm announced that its cancer drug candidate did not meet its…
Berwyn-based Warren Avenue Investors, a real estate firm formed by a former BioMed Realty executive, has established a $365 million venture with Ares Management…
Endo International, the Dublin-based pharmaceutical company with U.S. headquarters in Malvern, reached a $50 million settlement to resolve three opioid cases in New…
Endo International — based in Dublin, Ireland, with a U.S. headquarters in Malvern — has hired a financial restructuring firm to navigate its current legal morass…
Exton-based Recro Pharma has acquired its West Coast competitor, Irisys of San Diego, in a cash and stock deal valued at roughly $50 million…
Endo Health Solutions and Endo Pharmaceuticals — subsidiaries of Endo International, which is based in Dublin, Ireland, and has its U.S. headquarters in Malvern — have…
Malvern-based Galera Therapeutics recently triggered a $37.5 million payment by completing enrollment for a late-stage study of Avasopasem. John George reported on…
Wayne-based Cagent Vascular has received a $9 million investment from Sectoral Asset Management to accelerate the commercialization of its lead product, writes John George…
While even the majority of scientists working on mRNA vaccines for COVID-19 were shocked by its effectiveness, Katalin Karikó, an Abington biochemist and one…
Malvern-based PhaseBio Pharmaceuticals has signed an exclusive licensing agreement valued up to $245 million with Alfasigma of Italy, writes John George for the Philadelphia…
Malvern-based Ocugen has encountered a significant obstacle in its plans to bring the COVID-19 vaccine developed in India to the U.S., writes…
Exton-based Immunome is developing an “antibody cocktail” to fight COVID-19 variants of concern. The World Health Organization and Center for Disease Control classified…
Before we send you to this site, please subscribe to our daily newsletter.